Membranous nephropathy: setting the bar for hypothesis-driven, selective therapies in nephrology

J Nephrol. 2021 Apr;34(2):561-563. doi: 10.1007/s40620-020-00806-0.

Authors

Andrea Angeletti¹, Jeremy S Leventhal², Paolo Cravedi³

Affiliations

¹ Division of Nephrology, Dialysis, Transplantation, IRCCS Giannina Gaslini, Genoa, Italy.
² Division of Nephrology, White Plains Hospital, White Plains, NY, USA.
³ Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. paolo.cravedi@mssm.edu.

PMID: 32683657
DOI: 10.1007/s40620-020-00806-0

No abstract available

Keywords: Glomerulonephritis; Immune therapy; Membranous nephropathy; PLA2R; Rituximab.

Publication types

Editorial

MeSH terms

Autoantibodies
Glomerulonephritis, Membranous* / diagnosis
Glomerulonephritis, Membranous* / drug therapy
Humans
Nephrology*
Receptors, Phospholipase A2
Rituximab

Substances

Autoantibodies
Receptors, Phospholipase A2
Rituximab